**[10] GENE THERAPY MEETS IMMUNO-ONCOLOGY: VB-111 RESEARCH TRANSLATES TO OVERALL SURVIVAL**

**Dror Harats1, 1 Vascular Biogenics Ltd Operated As Vbl Therapeutics**

* **Investment Rational**
VBL-Therapeutics (NASDAQ: VBLT), is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer.
Our lead product, VB-111, is in Phase3 singly-needed pivotal trial in recurrent GBM under SPA, with Fast-Track status and Orphan designation in US and EU. VB-111 has demonstrated proof-of-concept in three Ph2 studies, which support its applicability for multiple solid-tumor indications.
Our seasoned management team, headed by Prof. Dror Harats, M.D, has extensive experience in vascular biology, oncology and drug development.
* **Business Strategy**
Our mission is to develop game-changing, innovative anti-cancer therapies. We intend to take VB-111 to commercialization through rGBM and establish collaboration with strategic-partner/s to advance VB-111 to additional cancer indications. In addition, we have a pipeline of assets in the immunology/oncology space that we can monetize/partner.
* **Core Technology**
VBL has pioneered the Vascular-Targeting-System-VTSTM, a First-in-Class gene-therapy platform technology which enables systemic administration of genes to destroy or promote angiogenic blood vessels. VTS is both tissue and condition-specific, allowing for targeted and limited gene-expression in endothelial cells undergoing angiogenesis.
* **Product Profile/Pipeline**
Lead product candidate VB-111 is a novel biologic agent that combines gene-therapy-based anti-angiogenic activity with an anti-tumor immune response. In Ph2 for rGBM VB-111 almost doubled the mOS, with statistical significance, relative to the standard-of-care. VB-111 also provided efficacy signal in Ph2 ovarian-cancer trial and demonstrated disease stabilization in Phase2a study for thyroid cancer. Beyond VB-111, we have additional pipeline assets that can be applicable for multiple indications.

**What's Next?**
VBL intends to meet with the FDA in 1Q/2Q16 to discuss the GBM program and for EOP2-meeting regarding VB-111 in ovarian cancer. Additional Ovarian and thyroid data are expected during 2016. The GLOBE study for VB-111 in rGBM is a Phase3 registration trial, with estimated interim in 1Q17 and completion in 4Q17. VBL has strong cash balance to execute its programs through 1H2018, beyond the readout of this singly-needed pivotal trial.